Business, energy, technology, markets and global industry news from Business News Today

Phase I/II trial

PharmaDeviceNews Phase I/II trial
Pharma & Biotech

How Clearmind Medicine is positioning CMND-100 within the emerging non-hallucinogenic neuroplastogen market

Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.

Read More
Pharma & Biotech

Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?

Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.

Read More